Glaxo Imitrex nasal spray will be launched with wholesale acquisition cost of $14.80 per dose.
GLAXO IMITREX NASAL SPRAY SET FOR OCTOBER LAUNCH following FDA approval Aug. 26, the company said. The wholesale acquisition cost of the intranasal migraine therapy will be $14.80 per dose, according to Glaxo Wellcome. The supplemental NDA for the intranasal formulation of sumatriptan (20-626) was submitted on Aug. 29, 1995, and became "approvable" on April 23.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth